Bayer's Stivarga Gets Approval In Japan To Treat Gastrointestinal Stromal Tumors

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said Tuesday that it has received approval from the Ministry of Health, Labor and Welfare or MHLW in Japan for the marketing of Stivarga or regorafenib for the treatment of patients with gastrointestinal stromal tumor or GIST who have progressed after prior systemic cancer therapy. This marks the second indication approved for Stivarga in Japan.

The company said that the approval of Stivarga was based on the positive results from the pivotal Phase III GRID (GIST - Regorafenib In Progressive Disease) trial that demonstrated a statistically significant improvement in progression-free survival or PFS compared to placebo in patients with GIST whose disease had progressed after treatment with imatinib mesylate and sunitinib malate.

Stivarga is approved in several countries, including the USA and Japan, for the treatment of patients with metastatic colorectal cancer or mCRC. Stivarga was recommended for approval by the European Committee for Medicinal Products for Human Use or CHMP for the treatment of adults with mCRC on June 27, 2013. The company noted that the decision of the European Commission on the marketing authorization is expected later in 2013.

GIST is the most common form of sarcoma arising from the muscle wall of the gastrointestinal tract. GIST represents a life-threatening malignancy if the disease has spread to other parts of the body (metastasized) or is unable to be surgically removed with curative intent.

Stivarga is an oral multi-kinase inhibitor that inhibits various kinases within the mechanisms involved in tumor growth and progression - angiogenesis, oncogenesis and the tumor microenvironment.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT